Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar 13:2014:604685.
doi: 10.1155/2014/604685. eCollection 2014.

Targeting mitochondria as therapeutic strategy for metabolic disorders

Affiliations
Review

Targeting mitochondria as therapeutic strategy for metabolic disorders

Daniela Sorriento et al. ScientificWorldJournal. .

Retraction in

Abstract

Mitochondria are critical regulator of cell metabolism; thus, mitochondrial dysfunction is associated with many metabolic disorders. Defects in oxidative phosphorylation, ROS production, or mtDNA mutations are the main causes of mitochondrial dysfunction in many pathological conditions such as IR/diabetes, metabolic syndrome, cardiovascular diseases, and cancer. Thus, targeting mitochondria has been proposed as therapeutic approach for these conditions, leading to the development of small molecules to be tested in the clinical scenario. Here we discuss therapeutic interventions to treat mitochondrial dysfunction associated with two major metabolic disorders, metabolic syndrome, and cancer. Finally, novel mechanisms of regulation of mitochondrial function are discussed, which open new scenarios for mitochondria targeting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mitochondrial dysfunction regulates insulin signaling. Insulin interacts with α-subunits of its receptor (IR) on cell membrane. In response to stimuli, tyrosine residues undergo autophosphorylation, and the IR phosphorylates the insulin-receptor substrate-1 (IRS-1) in serine residues, activating Akt, with phosphorylation of the type 4 glucose transporter (GLUT4) to the cell membrane and facilitation of glucose uptake. Mitochondrial dysfunction inhibits insulin signaling, leading to insulin resistance, by (1) interfering with oxidation of fatty acyl-CoA and consequent accumulation of diacylglycerol, with consequent activation of protein kinase C and phosphorylation of IRS-1 in tyrosine residues preventing its activation, and (2) through the generation of ROS, which inhibits IRS phosphorylation in serine residues.
Figure 2
Figure 2
Mitochondrial dysfunction and hypoxia in cancer. Schematic representation of the role of mitochondrial dysfunction in tumorigenesis. Damaged mitochondria release ROS which on turn activates HIF1α. Finally, HIF1α activates the tumorigenic hypoxia pathway by initiating transcription of genes involved in glucose metabolism, angiogenesis, and survival.

References

    1. Kim J-A, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circulation Research. 2008;102(4):401–414. - PMC - PubMed
    1. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiological Reviews. 1979;59(3):527–605. - PubMed
    1. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocrine Reviews. 2002;23(5):599–622. - PubMed
    1. Carreras MC, Franco MC, Peralta JG, Poderoso JJ. Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease. Molecular Aspects of Medicine. 2004;25(1-2):125–139. - PubMed
    1. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annual Review of Genetics. 2005;39:359–407. - PMC - PubMed

LinkOut - more resources